Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Tract Infection
Respiratory Syncytial Virus

Interventions

DRUG: Clesrovimab
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC